AUTHORS
Madhav Vissa, MD, Robert Ward Hagar, MD2, Karen Grant3, Marsha Treadwell, PhD4
AFFILIATIONS
1 University of California, San Francisco, Benioff Children's Hospitals, Oakland, California, United States
2 University of California, San Francisco, Benioff Children's Hospitals, Oakland, California, United States
3 University of California, San Francisco, Benioff Children's Hospitals, Oakland, California, United States
4 University of California, San Francisco, Benioff Children's Hospitals, Oakland, California, United States
ABSTRACT
Intro:
Adults with sickle cell disease (SCD) frequently require hospitalization for acute pain and other complications. The National Alliance of Sickle Cell Centers (NASCC) advises that sickle cell expertise be included in inpatient care. At the University of California, San Francisco (UCSF), adults seek care at multiple hospitals without in-house sickle cell expertise. We implemented a SCD eConsult service and other tools to standardize care, with the goals of improving access to subspecialty input, supporting clinical decision-making, and improving quality of care. We evaluated the utilization and impact of this eConsult service implementation on patient outcomes, including length of stay, 30-day readmissions, and provider satisfaction.
Methods:
The SCD eConsult service was implemented in July 2025. We conducted a retrospective cohort study of adult hospitalizations at UCSF, comparing pre-intervention (July 2023-June 2025) and post-intervention (July 2025-June 2026) periods. Outcomes of interest were utilization of the eConsult, length of stay (LOS), and 30-day acute care re-presentation (emergency or inpatient). Red blood cell transfusion during admission was assessed as a surrogate marker of clinical complexity. We evaluated these outcomes before and after the intervention, and in the post-intervention period, stratified by eConsult utilization. Continuous non-normal variables were compared using Wilcoxon rank-sum tests, and categorical variables were compared using chi-squared tests. We also conducted a provider survey to ascertain provider awareness, utilization, and perceived utility of the eConsult service.
Results:
There were 298 total admissions; 19 (6.4%) occurred at sites without eConsult access, representing an unmet need. The remaining 279 encounters were included (pre-intervention: n=187, post intervention: n=92). The cohort included 78 unique patients (median age 35.8 years [IQR 28.6-44.7]; 55.1% female; 89.7% identified as Black or African American). After implementation, eConsults were used in 46.7% of encounters. The inpatient general hematology consult service was also used more frequently after intervention (pre: 17.2% vs post: 30.4%), suggesting increased willingness to involve subspecialty consultation. LOS did not differ after intervention (pre: 5.2 days vs post: 6.5 days, p=0.38). However, 30-day readmissions (pre: 23.5% vs post: 45.7%, p<0.001) and overall re-presentations (pre: 35.3% vs post: 59.8%, p<0.001) increased.
Post-intervention, median LOS was significantly longer for encounters with an eConsult (eConsult: 10.1 days vs no eConsult: 4.3 days, p<0.001). Readmission rates were similar (eConsult: 46.5% vs no eConsult: 44.9%); however, there was a non-significant trend towards lower overall re-presentations when an eConsult was utilized (eConsult: 51.2% vs no eConsult: 67.3%, p=0.17). There was no significant difference in the frequency of transfusions before and after intervention (pre: 68.4% vs post: 70.7%, p=0.81), however, in the post-intervention period, encounters with an eConsult were more likely to include transfusions (eConsult: 86% vs no eConsult: 57.1%, p=0.005), suggesting greater clinical complexity. Survey responses (n=32) demonstrated variable awareness (59% aware) and utilization (41% previously utilized). Providers also reported variable likelihood of consulting for uncomplicated pain. However, providers reported high perceived clinical utility and overall favorable impressions of the eConsult service
Discussion:
Implementation of the sickle cell eConsult service was associated with rapid uptake and increased subspecialty involvement. Readmission rates increased during the post-intervention period, and encounters with eConsult utilization had significantly longer LOS. Encounters with eConsult utilization were also more likely to include transfusion, a surrogate of clinical severity. These findings suggest that eConsult use was concentrated among encounters with greater clinical complexity, rather than a direct adverse effect of the intervention. Provider survey data further support perceived utility, and ongoing efforts aim to improve awareness of the service and standardize care for adults with sickle cell disease.
DISCLOSURES
Madhav Vissa, MD: Novo Nordisk - Honoraria; CSL Behring - Research Funding; Novo Nordisk - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony)